Compare DLPN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | CUE |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 17.6M |
| IPO Year | 2008 | 2017 |
| Metric | DLPN | CUE |
|---|---|---|
| Price | $1.46 | $34.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 21.6K | ★ 21.2M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,699,389.00 | $27,466,000.00 |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.70 | ★ 195.75 |
| 52 Week Low | $0.99 | $0.17 |
| 52 Week High | $1.88 | $38.00 |
| Indicator | DLPN | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 83.39 |
| Support Level | $1.45 | $0.40 |
| Resistance Level | $1.65 | N/A |
| Average True Range (ATR) | 0.07 | 4.84 |
| MACD | 0.01 | 3.12 |
| Stochastic Oscillator | 52.17 | 81.55 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.